HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man.

Abstract
The kinetics of ethyl loflazepate were studied in patients with various degrees of renal failure. A strong correlation was noted between urinary excretion of metabolite loflazepate and creatinine clearance. In contrast, elimination half-life and total plasma clearance of the sum of loflazepate + descarboxyloflazepate seemed to be independent of the degree of renal impairment. These results indicate the absence of a risk of accumulation of the 2 main and active metabolites of ethyl loflazepate in patients with renal failure.
AuthorsB B Ba, A Iliadis, A Durand, Y Berger, J Necciari, J P Cano
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 3 Issue 1 Pg. 11-7 ( 1989) ISSN: 0767-3981 [Print] England
PMID2714728 (Publication Type: Journal Article)
Chemical References
  • Anti-Anxiety Agents
  • Benzodiazepinones
  • Benzodiazepines
  • ethyl loflazepate
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Anti-Anxiety Agents
  • Benzodiazepines
  • Benzodiazepinones (pharmacokinetics)
  • Female
  • Humans
  • Kidney Failure, Chronic (metabolism)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: